Anti-CD22 Antibody-Drug Conjugates for Targeted B Cell Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for additional drugs with lower toxicity but high therapeutic efficiency to treat B cell-related cancers such as non-Hodgkin's lymphoma and other B cell proliferative disorders, as existing treatments often result in severe side effects and limited efficacy.
Innovation Solution
Development of anti-CD22 antibody-drug conjugates that specifically target CD22 on B cells, utilizing monoclonal antibodies engineered with cysteine residues for site-specific conjugation of cytotoxic agents like auristatin peptides, allowing for targeted delivery and reduced toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy is used to treat B cell-related cancers, then therapeutic efficacy is achieved, but severe toxicity and side effects occur
Solution Approach 1:
The treatment approach is segmented into two distinct components: a targeting molecule (monoclonal antibody against CD22 or CD79b) and a cytotoxic agent. The antibody specifically binds to B cell surface antigens, delivering the cytotoxic payload selectively to malignant B cells while sparing normal cells, thereby maintaining efficacy while reducing systemic toxicity
Solution Approach 2:
A monoclonal antibody serves as an intermediary between the cytotoxic agent and the target cells. The antibody acts as a mediator that directs the cytotoxic payload to CD22+ or CD79b+ B cells through specific antigen binding, enabling targeted delivery and reducing off-target effects
2Reliability
If existing B cell targeted therapies are used, then some therapeutic effect is achieved, but treatment options are limited and resistance develops
Solution Approach 1:
The invention provides multiple antibody targets (CD22 and CD79b) that can be used against the same disease indication (B cell malignancies). This multi-target approach expands treatment options and allows selection of appropriate targets based on disease subtype, patient history, and resistance patterns
Solution Approach 2:
Different cytotoxic payloads are conjugated to the targeting antibodies, varying the mechanism of action and potency parameters. This allows optimization of therapeutic effect for different clinical scenarios and overcomes resistance by selecting payloads with different mechanisms
3Reliability
If non-specific cytotoxic agents are used, then cell death is induced, but normal cells are also harmed
Solution Approach 1:
The cytotoxic effect is localized specifically to B cells expressing the target antigen (CD22 or CD79b). The monoclonal antibody ensures that the cytotoxic payload is delivered only to cells with the appropriate surface marker, creating a locally concentrated effect at the target site while leaving normal cells unaffected
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The anti-CD22 antibody-drug conjugates demonstrate enhanced therapeutic efficiency with reduced toxicity by specifically binding to CD22 on B cells, facilitating targeted delivery of cytotoxic agents and inducing cell death while minimizing harm to normal cells.
Implementation Method 1
anti-CD22 antibodies and immunconjugates thereof... antibody that binds to CD22
Implementation Method 2
monoclonal antibodies engineered with cysteine residues for site-specific conjugation of cytotoxic agents
Implementation Method 3
facilitating targeted delivery of cytotoxic agents and inducing cell death while minimizing harm to normal cells
Data Source
Figure 1A
Figure 1B~1D
Figure 2A
AI summary
Anti-CD22 antibodies and immunoconjugates thereof are provided. Methods of using anti-CD22 antibodies and immunoconjugates thereof are provided.